Results 11 to 20 of about 2,198,265 (159)

The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective [PDF]

Hellenic Journal of Cardiology, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed disease associated with high mortality rates and the patient journey is characterized by increased complexities.
Efstratios A. Apostolou, Anna-Maria Fontrier, Georgios K. Efthimiadis, Efstathios Kastritis, John Parissis, Panos Kanavos   +5 more
doaj   +4 more sources

The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis [PDF]

European Journal of Heart Failure
Aims: Several scores were developed to help the diagnosis of cardiac amyloidosis (CA). The most recent one, being the Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score, was not externally validated.
Giovanni Battista Bonfioli
exaly   +4 more sources

Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan [PDF]

ESC Heart Failure, 2023
Aims Heart failure with preserved ejection fraction (HFpEF), which is caused by wide various conditions, has become a major public health problem. Transthyretin amyloid cardiomyopathy (ATTR‐CM), which is thought to be an underdiagnosed disease, can cause
Takanori Naito, Kazufumi Nakamura, Yukio Abe, Hiroyuki Watanabe, Satoru Sakuragi, Yusuke Katayama, Hajime Kihara, Atsutaka Okizaki, Yusuke Kawai, Masaki Yoshikawa, Atsushi Takaishi, Hideki Fujio, Hiroaki Otsuka, Soichiro Ogura, Hiroshi Ito, ATTR‐HFpEF registry investigators   +15 more
doaj   +3 more sources

Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review

Biomedicines, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed condition. Although wild-type transthyretin amyloidosis (ATTRwt) is the most common ATTR-CM, hereditary transthyretin amyloidosis (ATTRv) may also occur.
Ana-Maria Merino-Merino, Jorge Labrador-Gomez, Ester Sanchez-Corral, Pedro-David Delgado-Lopez, Jose-Angel Perez-Rivera   +4 more
doaj   +2 more sources

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure
Aims Data on the clinical profiles of patients with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) in the post‐approval era of tafamidis 61 mg are lacking.
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
doaj   +2 more sources

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. [PDF]

Cardiol Ther, 2021
Introduction: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal and under-recognized disease. This targeted literature review assessed the extent and consequences of diagnostic delay and misdiagnosis in ATTR-CM.
Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, Dasgupta N, Masri A, Nativi-Nicolau J.   +8 more
europepmc   +2 more sources

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). [PDF]

Glob Heart, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment.
Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Piñero D, Rapezzi C, Ueda M, Pinto FJ.   +18 more
europepmc   +5 more sources

Early Diagnosis of ATTR-CM by Age- and Carpal Tunnel Biopsy-Guided Screening. [PDF]

JACC Adv
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is frequently preceded by carpal tunnel syndrome (CTS). The value of age- and biopsy-guided screening during CTS surgery for early detection of ATTR-CM remains uncertain.
Fensman SK, Ladefoged BT, Hartig-Andreasen C, Stilling C, Mejren AHJ, Beck HC, Clemmensen TS, Poulsen SH.   +7 more
europepmc   +2 more sources

Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review. [PDF]

J Comp Eff Res
Aim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are ...
Nativi-Nicolau J, Yilmaz A, Dasgupta N, Macey R, Cochrane J, Peatman J, Summers C, Luth J, Zolty R.   +8 more
europepmc   +2 more sources

Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients

BMC Cardiovascular Disorders, 2023
Background Transthyretin amyloidosis cardiomyopathy (ATTR-CM) patients are often older and may be at risk for obstructive epicardial coronary artery disease (oeCAD).
Rana Hassan, Robert J. H. Miller, Jonathan G. Howlett, James A. White, Nowell M. Fine   +4 more
doaj   +1 more source